JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

Search

Guardant Health Inc

Gesloten

SectorGezondheidszorg

72.17 4.31

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

69.34

Max

72.53

Belangrijke statistieken

By Trading Economics

Inkomsten

-4.7M

-100M

Verkoop

29M

232M

Winstmarge

-43.044

Werknemers

1,999

EBITDA

22M

-89M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+5.6% upside

Dividenden

By Dow Jones

Volgende Winsten

29 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.3B

8.8B

Vorige openingsprijs

67.86

Vorige sluitingsprijs

72.17

Nieuwssentiment

By Acuity

21%

79%

45 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Guardant Health Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 okt 2025, 20:49 UTC

Winsten

Correction to Thermo Fisher Article on Oct. 22

23 okt 2025, 23:51 UTC

Marktinformatie

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 okt 2025, 23:49 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 okt 2025, 23:49 UTC

Marktinformatie

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 okt 2025, 23:37 UTC

Marktinformatie

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 okt 2025, 22:58 UTC

Marktinformatie

Global Energy Roundup: Market Talk

23 okt 2025, 22:57 UTC

Marktinformatie

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 okt 2025, 22:49 UTC

Acquisities, Fusies, Overnames

How Trump Sparked a New Era of State Capitalism -2-

23 okt 2025, 22:49 UTC

Acquisities, Fusies, Overnames

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 okt 2025, 22:17 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 okt 2025, 21:41 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 okt 2025, 21:05 UTC

Winsten

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

23 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

23 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 okt 2025, 20:35 UTC

Winsten

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 okt 2025, 20:28 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 okt 2025, 20:15 UTC

Marktinformatie
Winsten

Global Commodities Roundup: Market Talk

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q Adj EPS $1.71

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q Sales $5.52B

23 okt 2025, 20:10 UTC

Winsten

Newmont Mining 3Q EPS $1.67

23 okt 2025, 20:09 UTC

Winsten

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 okt 2025, 20:07 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

23 okt 2025, 20:07 UTC

Marktinformatie
Winsten

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 okt 2025, 20:07 UTC

Winsten

Blackstone Looks to IPOs for Investment Exits -- Update

23 okt 2025, 20:05 UTC

Winsten

Intel 3Q Gross Margin 38.2% >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 okt 2025, 20:04 UTC

Winsten

Intel: 4Q Guidance Excludes Altera >INTC

23 okt 2025, 20:04 UTC

Winsten

Intel Sees 4Q Adj EPS 8c >INTC

Peer Vergelijking

Prijswijziging

Guardant Health Inc Prognose

Koersdoel

By TipRanks

5.6% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 71.84 USD  5.6%

Hoogste 90 USD

Laagste 60 USD

Gebaseerd op 21 Wall Street-analisten die 12-maands prijsdoelen bieden voor Guardant Health Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

21 ratings

21

Buy

0

Hold

0

Sell

Technische score

By Trading Central

38.86 / 47.41Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

45 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat